Search

FDA approves Phase III trial of synthetic biological COVID-19 treatment

Updated: Jan 19

Source :https://www.healthcarefinancenews.com/news/covid-19-treatment-first-synthetic-biological-drug-receive-fda-approval-phase-3-trials


Jan 05, 2021 | By Jeff Lagasse, Associate Editor


Carrimycin includes antiviral, anti-inflammatory and anti-fibrosis effects in addition to its antibacterial effect.



Carrimycin has become the world's first synthetic biological drug treatment for severe COVID-19 to receive U.S. Food and Drug Administration approval for Phase III trials. Testing has shown that Carrimycin is effective in treating patients who have been hospitalized with severe coronavirus symptoms, helping them recover within 14 days from the worst impacts of the disease.


JAN 04MORE ON PHARMACY

COVID-19 treatment is the first synthetic biological drug to receive FDA approval for Phase 3 trials

Carrimycin includes antiviral, anti-inflammatory and anti-fibrosis effects in addition to its antibacterial effect.

Jeff Lagasse, Associate Editor

Carrimycin has become the world's first synthetic biological drug treatment for severe COVID-19 to receive U.S. Food and Drug Administration approval for Phase III trials. Testing has shown that Carrimycin is effective in treating patients who have been hospitalized with severe coronavirus symptoms, helping them recover within 14 days from the worst impacts of the disease. Carrimycin includes antiviral, anti-inflammatory and anti-fibrosis effects, in addition its antibacterial effect. It was originally designed to treat community-acquired infections in adults caused by sensitive bacteria. It was developed in China by the Tonglian Group using synthetic biology technology.


WHAT'S THE IMPACT?


Laboratory tests in early 2020 showed it has a strong anti-coronavirus effect, inhibiting the replication of COVID-19 in cells without causing significant side effects. The Phase III trials are building on testing carried out in China, the results of which have been recognized by the FDA.


Tonglian Group CEO Jiang Enhong called the international collaboration a "major breakthrough."


"The availability of vaccines is, of course, very important," said Enhong. "But we know there will always be people who contract COV